

Dear Dr Jin-Rei Wang,

Company Editor-in-Chief, Editorial Office, World Journal of Hepatology,

Thank you for reviewing and providing the chance of revision regarding with our work.

Please find attached our revised manuscript entitled “**Direct-acting antivirals for HCV-infected patients with hepatocellular carcinoma**” by K. Tajiri, *et al* for consideration of publication in *World Journal of Hepatology*.

We revised our manuscript according to reviewers’ helpful comments point by point as shown below. Revised sentences were shown in **red font**. We believe it offers useful and helpful information for clinicians.

Reviewer #1

Thank you for reviewing our manuscript and providing your comments.

Reviewer #2

Thank you for reviewing our manuscript and providing your valuable comments.

- 1) As reviewer #2 mentioned, alcohol abuse is an important risk factor for HCC. We evaluated alcohol use in present cohort. But the number of patients with habitual alcohol consumption was limited, and risk increase due to alcohol was unclear in present cohort. We have added the results in the RESULTS section (page 9, lines 6 and 7) and Table 1 and 3.
- 2) The possible mechanism for the good course of DAA-treated patients was described in the discussion (page 13, lines 9 and 10).

Science Editor

Thank you for your comments. According to the editor’s comments, references from the same journal were adjusted. The flow chart of study design was prepared as supplementary figure 1. The tables were corrected to word format separated from figures.

I hope the revised manuscript is suitable for publication in *World Journal of Hepatology*.

Sincerely yours,

Kazuto Tajiri, MD, PhD
The Third Department of Internal Medicine,
University of Toyama,
TEL: 81-76-434-7301,
FAX: 81-76-434-5027
e-mail: tajikazu@med.u-toyama.ac.jp